Mizuho analyst Difei Yang raised his price target for Novocure to $58 after the company reported final results from the Phase 2 trial of Optune plus standard chemotherapy in mesothelioma patients. Data were “impressive” with an overall survival benefit of 6.1 months compared to historical controls, Yang tells investors in a research note. She believes the data reinforce the potential of Optune in additional cancers outside of the brain including non-small cell lung cancer. The analyst reiterates a Buy rating on Novocure.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.